Berenberg Bank Reiterates €88.85 Price Target for Fresenius Medical Care AG & Co. KGaA (FME)

Fresenius Medical Care AG & Co. KGaA (ETR:FME) received a €88.85 ($103.31) price objective from equities researchers at Berenberg Bank in a report released on Tuesday, February 5th. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s price objective would suggest a potential upside of 30.47% from the company’s previous close.

Several other research firms have also commented on FME. JPMorgan Chase & Co. set a €84.20 ($97.91) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a report on Wednesday, November 7th. Kepler Capital Markets set a €100.00 ($116.28) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a report on Wednesday, November 7th. Morgan Stanley set a €93.00 ($108.14) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research report on Wednesday, November 7th. Barclays set a €76.00 ($88.37) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research report on Wednesday, November 7th. Finally, HSBC set a €90.00 ($104.65) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research report on Tuesday, December 4th. Nine analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of €82.75 ($96.22).

Shares of FME stock opened at €68.10 ($79.19) on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of €75.53 ($87.83) and a 1-year high of €93.82 ($109.09).

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Further Reading: What is a Derivative?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply